Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 10Neoplasms 9Carcinoma 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasm Metastasis 3Melanoma 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Lung Neoplasms 2Kidney Diseases 2Glioblastoma 2Carcinoma, Adenoid Cystic 2Breast Neoplasms 2Advanced Solid Tumors 2cT2a N0NxM0 Renal Tumor 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Malignancies 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Salivary Gland Neoplasms 1Refractory or Recurrent Solid Tumors, Excluding CNS Tumors 1Prostatic Neoplasms 1

Interventions

Cyclophosphamide 110fludarabine phosphate 106Busulfan 84Azacitidine 73Peripheral Blood Stem Cell Transplantation 64Mycophenolic Acid 64Antilymphocyte Serum 64Cytarabine 63Tacrolimus 62fludarabine 61Cyclosporine 56Filgrastim 55Whole-Body Irradiation 52Methotrexate 47Melphalan 42Decitabine 42Radiotherapy 37Clofarabine 29Granulocyte Colony-Stimulating Factor 28Cord Blood Stem Cell Transplantation 28Methylprednisolone 24Etoposide 24thymoglobulin 21Thiotepa 21Stem Cell Transplantation 21sargramostim 19Sirolimus 16Alemtuzumab 15Lenalidomide 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelodysplastic Syndromes × Axitinib × Clear all
NCT00071006 2012-06-08

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Pfizer

Phase 2 Completed
12 enrolled 5 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡